Identifcaiton of cancer stem cells in HNSCC

2021 Fiscal Year Final Research Report

• Project/Area Number: 18K09334
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 56050:Otorhinolaryngology-related
• Research Institution: Miyagi Prefectural Hospital Organization Miyagi Cancer Center
• Principal Investigator: Morita Shinkichi 地方独立行政法人宮城県立病院機構宮城県立がんセンター(研究所), がん幹細胞研究部, 特任研究員 (10773955)
• Co-Investigator(Kenkyū-buntansha): 玉井 恵一 地方独立行政法人宮城県立病院機構宮城県立がんセンター(研究所), がん幹細胞研究部, 部長 (40509262)
• Project Period (FY): 2018-04-01 – 2022-03-31
• Keywords: 下咽頭癌

Outline of Final Research Achievements

This study aims to test whether CD271, which is a stem cell marker in hypopharyngeal cancer, is a good target in therapy. A humanized anti-CD271 antibody was developed. The antibody possessed antibody-dependent cellular cytotoxicity capacity against cancer cells in vitro. Antibody administration in mice bearing human cancer cells led to tumor volume suppression. CD271-positive cancer cells in the antibody-treated mice decreased. Collectively, the CD271 antibody treatment for hypopharyngeal cancer is a promising therapy.

Free Research Field

腫瘍生物学

Academic Significance and Societal Importance of the Research Achievements

本研究では抗CD271抗体が癌の治療に使えることをマウスモデルを用いて示した。今後更に検討を重ね、臨床応用の検討を進める。